News

GlobalData on MSN1d
Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand
Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.
Novo Nordisk Stock Jumps Despite Full-Year Outlook Cut
U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...
Novo Nordisk Q1 2025: One Of The Best Deals You Can Get Right Now
Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...
Novo Nordisk teams with telehealth firms Hims, Ro to sell Wegovy at lower price
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...
Novo Nordisk Gains as CFO Touts Wegovy’s Rebound Potential
Novo Nordisk A/S surged on expectations that some competition for its blockbuster obesity shot Wegovy will subside, paving ...
Wegovy Deal Makes Cofounder Of Hair Loss Pill Seller Hims A Billionaire
Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...
Novo Nordisk shares pop as drugmaker sees copycat Wegovy sales easing in 2025
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast ...
pharmaphorum6d
Lilly hit as PBM drops Zepbound, but retains Wegovy
Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...